The Worst Combination for Coronary Artery Disease Under Strong-Statin Therapy Is Chronic Kidney Disease and Diabetes　― Non-Lipid Residual Risk Assessment From the REAL-CAD Study ―-Reference-Cited by-同舟云学术

The Worst Combination for Coronary Artery Disease Under Strong-Statin Therapy Is Chronic Kidney Disease and Diabetes　― Non-Lipid Residual Risk Assessment From the REAL-CAD Study ―

Published:2023-10-19 Issue: Volume: Page:
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Nohara Atsushi¹

Affiliation:

1. Ishikawa Prefectural Central Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-23-0694/_pdf

Reference9 articles.

1. 1. Gaba P, O’Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: An analysis of FOURIER-OLE. Circulation 2023; 147: 1192–1203.

2. 2. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387: 1923–1934.

3. 3. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849–1861.

4. 4. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117–127.

5. 5. Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022; 42: e168–e185.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis;Cardiovascular Intervention and Therapeutics;2024-06-17